These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3842 related items for PubMed ID: 15531001

  • 1. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, STELLAR Study Group.
    Curr Med Res Opin; 2003 Sep; 19(8):689-98. PubMed ID: 14687438
    [Abstract] [Full Text] [Related]

  • 3. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
    Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H.
    Int J Cardiol; 2005 Apr 20; 100(2):309-16. PubMed ID: 15823640
    [Abstract] [Full Text] [Related]

  • 4. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.
    Am Heart J; 2006 May 20; 151(5):975.e1-9. PubMed ID: 16644314
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 20; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group.
    Am Heart J; 2004 Apr 20; 147(4):705-13. PubMed ID: 15077101
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M.
    Am Heart J; 2004 Jul 20; 148(1):e4. PubMed ID: 15215813
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M, O'Donnell JC, Jones P.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb 20; 12(1):18-28. PubMed ID: 15703502
    [Abstract] [Full Text] [Related]

  • 14. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ, Davidson MH, Caplan RJ, Pears JS.
    Am J Cardiol; 2003 Mar 06; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [Abstract] [Full Text] [Related]

  • 15. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
    Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, Rosuvastatin Investigators Group.
    Am Heart J; 2002 Dec 06; 144(6):1044-51. PubMed ID: 12486429
    [Abstract] [Full Text] [Related]

  • 16. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug 06; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
    Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E, Rosuvastatin Study Group.
    Am Heart J; 2002 Dec 06; 144(6):1036-43. PubMed ID: 12486428
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, Lowe RS, Hanson ME, Tershakovec AM.
    J Clin Lipidol; 2011 Dec 06; 5(6):474-82. PubMed ID: 22108151
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 193.